IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis
Authors:
Open Access
- 7 June 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 17 (6) , e0011364
Abstract
Background: Lymphatic filariasis (LF) is a neglected tropical disease and a major cause of chronic disability. Improved diagnostic tests are needed because of long-term persistence of anti-filarial antibodies or circulating filarial antigenemia after treatments that clear microfilaremia. Here, we assess changes in levels of antibodies to the recombinant filarial antigens Wb-Bhp-1, Wb123, and Bm14 after anti-filarial treatment. Methodology/principal findings: IgG4 antibodies to recombinant filarial antigens were assessed by ELISA. We tested serial plasma samples from a clinical trial in Papua New Guinea. Before treatment, 90%, 71% and 99% of participants had antibodies to Wb-Bhp-1, Wb123, and Bm14, respectively. Antibodies to Wb-Bhp-1 and Wb123, but not Bm14, were significantly higher in participants with persistent microfilaremia 24 months after treatment. Antibodies to all three antigens declined significantly by 60 months after treatment with ivermectin, diethylcarbamazine and albendazole despite circulating filarial antigen in 76% of participants. By 60 months follow up, antibodies to Wb-Bhp-1, Wb123, and Bm14 were detected in 17%, 7% and 90% of participants, respectively. Antibodies to Wb-Bhp-1 also declined more rapidly after treatment than antibodies to Bm14 in samples from a clinical trial conducted in Sri Lanka. We also tested archived serum samples from people living in filariasis-endemic communities in Egypt with different infection profiles. Antibodies to Wb-Bhp-1 were detected in 73% of microfilaremic people, 53% of amicrofilaremic people with circulating filarial antigen, and 17.5% of endemic individuals without microfilaria or circulating filarial antigen. Tests performed with legacy samples from India showed that few people with filarial lymphedema had antibodies to these recombinant antigens. Conclusions: Antibodies to Wb-Bhp-1 and Wb123 are more closely correlated with persistent microfilaremia than circulating filarial antigenemia or antibodies to Bm14, and they clear more rapidly after anti-filarial treatment. Additional studies are needed to assess the value of Wb-Bhp-1 serology as a tool for determining the success of LF elimination efforts.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-021433)
- Bill and Melinda Gates Foundation (OPP1201530)
- Foundation for Barnes-Jewish Hospital (4618)
- Foundation for the National Institutes of Health (T32 HD043010)
This publication has 33 references indexed in Scilit:
- Antibody to the Filarial Antigen Wb123 Reflects Reduced Transmission and Decreased Exposure in Children Born following Single Mass Drug Administration (MDA)PLOS Neglected Tropical Diseases, 2012
- Identification of Wb123 as an Early and Specific Marker of Wuchereria bancrofti InfectionPLOS Neglected Tropical Diseases, 2012
- Transcription profiling reveals stage- and function-dependent expression patterns in the filarial nematode Brugia malayiBMC Genomics, 2012
- A Deep Sequencing Approach to Comparatively Analyze the Transcriptome of Lifecycle Stages of the Filarial Worm, Brugia malayiPLOS Neglected Tropical Diseases, 2011
- Stage-specific proteomic expression patterns of the human filarial parasiteBrugia malayiand its endosymbiontWolbachiaProceedings of the National Academy of Sciences, 2011
- Immune responses to recombinant Brugia malayi pepsin inhibitor homolog (Bm-33) in patients with human lymphatic filariaisisParasitology Research, 2010
- The Impact of Repeated Rounds of Mass Drug Administration with Diethylcarbamazine Plus Albendazole on Bancroftian Filariasis in Papua New GuineaPLOS Neglected Tropical Diseases, 2008
- Stage- and Gender-Specific Proteomic Analysis of Brugia malayi Excretory-Secretory ProductsPLOS Neglected Tropical Diseases, 2008
- Serum immune complexes as diagnostic and therapeutic markers in lymphatic filariasisJournal of Clinical Laboratory Analysis, 2007
- Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazineTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996